-
Bavarian Nordic Announces Interim Results for the First Nine Months of 2023
Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2023 and business progress for the third quarter of 2023. Revenue for the first nine months increased by 148% to DKK 4,615 million compared to the same period last year, while the operating profit (EBITDA) increased to DKK 1,552 million. The increased revenue was driven by growth across both business areas: travel health and public preparedness. Revenue from travel health grew by 56% to DKK 1,608 million, as a result of the continued rebound in global travel, strong brand performance and the recent expansion of the travel health portfolio. Revenue from public preparedness…
-
Bavarian Nordic to Host Third Quarter 2023 Results Conference Call and Webcast
Bavarian Nordic A/S (OMX: BAVA) will announce its 2023 third quarter results on Thursday, November 16, 2023. The management of Bavarian Nordic will host a conference call at 2:00 pm CET (8:00 am EST) on the same day to present the interim results followed by a Q&A session. A listen-only version of the call and presentation slides can be accessed via https://bit.ly/3tonMNp. To join the Q&A session, please register in advance via https://bit.ly/48Cp0F2. Über die Bavarian Nordic GmbH Bavarian Nordic is a fully integrated vaccine company focused on the research and development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox and mpox vaccines, which have been developed…
-
Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve
Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded another contract valued at more than EUR 11 million to supply its MVA-BN® smallpox vaccine to rescEU, a strategic reserve within the European Union (EU). This order follows an initial contract awarded in June 2023 and is also for delivery in 2024. The vaccines will be stockpiled in another EU country thus expanding the EU’s capability to respond to biological threats and emergencies in the future by enabling rapid deployment of medical countermeasures to its member states and other countries participating in the EU Civil Protection Mechanism. Paul Chaplin, President & CEO of Bavarian Nordic, said: “We are pleased to continue…
-
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government
Contract award will support manufacturing of new bulk vaccine to partly replenish the inventory used for the mpox outbreak in 2022 Aims to strengthen the long-term U.S. stockpiling of smallpox vaccines Company upgrades its financial guidance for 2023 Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, has placed a new order valued at USD 120 million, primarily covering the manufacturing of new bulk product for the Company’s smallpox/mpox vaccine. The bulk product, representing USD 96 million of the contract value, will be…
-
Bavarian Nordic Publishes Annual Report 2022
Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2022. The consolidated, audited results were in line with the preliminary results, announced on January 16, 2023. The full report is attached as a PDF file and can be found on the company’s website, www.bavarian-nordic.com. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “We proudly delivered all-time high revenues in 2022 resulting from significant deliveries of mpox vaccine to countries worldwide during the outbreak, combined with a strong performance in the rabies business, particularly in the US. The travel vaccine market is rebounding, and we are anticipating stronger sales in 2023, which in combination with continued…
-
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate
First subject vaccinated in Phase 3 clinical trial evaluating potential of the VLP-based candidate, ABNCoV2 as a booster COVID-19 vaccine Trial will assess non-inferiority of ABNCoV2 compared to Comirnaty® in terms of neutralizing antibodies against the SARS-CoV-2 (Wuhan wild type) as the primary endpoint, and other variants of concern as secondary endpoints Bavarian Nordic A/S (OMX: BAVA) announced today the dosing of the first subject in the Phase 3 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate. The double-blind, controlled Phase 3 clinical trial will enroll approximately 4,000 adult subjects who either previously completed primary vaccination or have already received one booster dose of a licensed COVID-19…
-
Bavarian Nordic Enters Multiple Vaccine Contracts with Governments in Response to Global Monkeypox Outbreak
A number of contracts of varying size have been signed Deliveries to start immediately aiming to ensure a rapid response to the current monkeypox outbreak Company upgrades its financial guidance for 2022 Bavarian Nordic A/S (OMX: BAVA) announced today the signing of a number of supply contracts with undisclosed countries for the Company’s smallpox vaccine with the aim to ensure sufficient supply to meet the requirements for vaccinating individuals at risk for monkeypox in the short to medium term. The vaccine is approved for use against monkeypox by the U.S. Food and Drug Administration and Health Canada as the only vaccine having obtained regulatory approval for this indication in…
